Prinston Recalls Irbesartan and Hydrochlorothiazide Tablets Due to Labeling Error
Prinston Pharmaceutical Inc. is recalling Irbesartan and Hydrochlorothiazide tablets because an incorrect lot number appears on the case label.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as unlikely to cause adverse health consequences. The issue is a documentation/labeling discrepancy regarding the lot number on the case label.
Plain-English summary
Prinston Pharmaceutical Inc. is recalling 60 bottles (5 cases) of Irbesartan and Hydrochlorothiazide Tablets, USP, 300/12.5 mg, Rx only. The product is manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. and distributed by Solco Healthcare U.S., LLC. The recall is limited to Lot # 327B16002 with an expiration date of 12/17.
The recall was initiated due to a labeling error. The case label displays an incorrect lot number, 327B160012, while the correct lot number, 327B16002, appears on the immediate container. The FDA has classified this as a Class III recall, indicating that the violation is not likely to cause adverse health consequences.
The affected product was distributed nationwide. Consumers and healthcare providers should check their inventory for this specific lot and expiration date. If found, the product should be returned to the pharmacy or distributor for credit or replacement.
The recalled product
- Product
- IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)
- Brand
- IRBESARTAN AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Prinston Pharmaceutical Inc
- Category
- Drug — Prescription Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 327B16002
- Exp 12/17
UPCs (2)
- 0343547331030
- 0343547330033
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · IRBESARTAN AND HYDROCHLOROTHIAZIDE
- SeverePrinston Recalls Irbesartan and Hydrochlorothiazide Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-02-06
- SeverePrinston Recalls Irbesartan and Hydrochlorothiazide Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-02-06
- SeverePrinston Recalls Irbesartan and Hydrochlorothiazide Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-02-06
- SeverePrinston Recalls Irbesartan and Hydrochlorothiazide Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-02-06
- LowTeva Recalls Irbesartan and Hydrochlorothiazide Tablets Due to Labeling Errors
FDA (Drugs) · 2015-12-23
Same manufacturer · Prinston Pharmaceutical Inc
See all →- SeverePrinston Recalls Irbesartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-02-06
- SeverePrinston Recalls Valsartan and Hydrochlorothiazide Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-01
- SeverePrinston Recalls Valsartan and Hydrochlorothiazide Tablets Due to Carcinogen Impurity
FDA (Drugs) · 2018-08-01
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02